Company

Atriva Therapeutics, founded in 2015, is a biopharmaceutical company specifically pioneering the development of host-targeting antiviral therapies set up by a team of leading scientists in viral research and seasoned industry experts. The Company aims to develop new antiviral therapies against different severe respiratory viral infections with a high unmet medical need, such as influenza and COVID-19.

Atriva’s lead product ATR-002 is a first-in-class host-targeting agent which inhibits viral replication in influenza and favorably modulates the body’s immune response. ATR-002 has successfully completed a Phase I trial to demonstrate safety and tolerability in healthy subjects (NCT04385420). A Phase II study to evaluate efficacy in hospitalized COVID-19 patients obtained approval from German drug authority (BfArM) and will start in due course. Clinical Phase II in influenza is planned for the second half of 2021.

Its mechanism of action offering a dual benefit – antiviral activity and immunomodulation – uniquely positions ATR-002 as a promising therapeutic candidate which holds strong potential in the current COVID-19 pandemic. The small molecule could prevent a cytokine storm and the associated disease progression to a life-threatening condition in patients with COVID-19. Treating moderately to severely-ill patients aims to reduce the number of critically ill people, otherwise referred to ICUs and requiring more invasive treatment options. This could fundamentally impact COVID-19 outcomes and can be vital for national health systems, patients and families.

Atriva Therapeutics owns eleven patent families with broad international coverage related to the use of MEK inhibitors and other kinase inhibitors for anti-viral therapies. The patent life runs through 2041. The Company is located in Frankfurt/Main and Tübingen, Germany.

 

 

 

 

Atriva About us

Address

Atriva Therapeutics GmbH
Eisenbahnstr. 1, 72072 Tübingen

+49 (0)7071 8597673
info@atriva-therapeutics.com

LinkedIn
Twitter

In order to be able to design our website in the best possible way and to continuously improve it, we are using cookies. By continuing to use our website, you permit the use of cookies. More information can be found in our data protection rules.